Loading clinical trials...
Loading clinical trials...
A Phase Ib Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Conditions
Interventions
Ivosidenib
Enasidenib
+1 more
Locations
1
United States
University of Chicago Medical Center
Chicago, Illinois, United States
Start Date
October 29, 2021
Primary Completion Date
June 7, 2023
Completion Date
June 7, 2023
Last Updated
July 31, 2024
NCT06782542
NCT06636162
NCT06611839
NCT03991832
NCT03749187
NCT05406700
Lead Sponsor
University of Chicago
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions